Skip to main content
. 2019 Nov 15;29(4):286–295. doi: 10.1136/bmjqs-2018-009177

Table 4.

Incremental economic analysis of NMS versus normal practice at 26-week follow-up

Mean cost (2.5%, 97.5% percentiles)/£ Mean QALY (2.5%, 97.5% percentiles) Incremental difference (2.5%, 97.5% percentiles) ICER: £/QALY (2.5%, 97.5% percentiles)
NMS* Normal practice NMS Normal practice Cost/£ QALY
20 482.7 (9438.9, 53 822.0) 20 596.5 (9435.5, 54 125.5) 13.45 (12.55, 14.35) 13.41 (12.50, 14.31) −113.9 (−1159.4, 683.7) 0.04 (−0.01, 0.13) −2847.5 (−38 739.5, 34 024.2)

*Incorporating cost of intervention equal to £24.6.

ICER, incremental cost-effectiveness ratio; NMS, New Medicine Service; QALY, quality-adjusted life-year.